Drug Type Small molecule drug |
Synonyms BMS 986371, BMS-986371, BMS986371 + [2] |
Target |
Action inhibitors |
Mechanism MAPKAPK2 inhibitors(MAP kinase-activated protein kinase 2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H20ClN5O3S |
InChIKeyPYOQIOLRFIRRSO-LLVKDONJSA-N |
CAS Registry1887069-10-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ankylosing Spondylitis | Phase 2 | United States | 25 Aug 2021 | |
Ankylosing Spondylitis | Phase 2 | Czechia | 25 Aug 2021 | |
Ankylosing Spondylitis | Phase 2 | Germany | 25 Aug 2021 | |
Ankylosing Spondylitis | Phase 2 | Poland | 25 Aug 2021 | |
Ankylosing Spondylitis | Phase 2 | Romania | 25 Aug 2021 | |
Ankylosing Spondylitis | Phase 2 | Spain | 25 Aug 2021 | |
Ankylosing Spondylitis | Phase 2 | Turkey | 25 Aug 2021 | |
Inflammation | Phase 1 | United Kingdom | 23 May 2018 |
Phase 2 | 167 | Placebo (Placebo Biologic Naive) | kixbxgglhk = awgyzokjdl loxqtcgoko (owjsjfvqku, pmrnavohtc - owmwtkfwjs) View more | - | 01 May 2024 | ||
(CC-99677 60 mg Biologic Naive) | kixbxgglhk = aetbhcngjo loxqtcgoko (owjsjfvqku, ivtxmucxzx - njwwmxdmzu) View more |